흡입 및 비강 스프레이 제네릭 의약품 시장 규모, 점유율 및 동향 분석 보고서 : 약품 유형별, 적응증별, 환자군별, 최종 용도별, 유통 채널별, 지역별, 부문별 예측(2025-2030년)

Inhalation And Nasal Spray Generic Drugs Market Growth & Trends:

The global inhalation and nasal spray generic drugs market size is expected to reach USD 49.09 billion by 2030, registering a CAGR of 8.56% from 2025 to 2030, according to a new report by Grand View Research, Inc. New product launches, mounting prevalence of chronic respiratory diseases, growing demand for cost-effective medicines, and rising geriatric population are some of the major factors boosting the market growth.

Rising demand for cost-effective medicines and government support for the use of generics is expected to drive the demand for inhalation and nasal spray generic drugs over the forecast period. For instance, the Government of Japan has been promoting the usage of inexpensive generic drugs in order to regulate the overall pharmaceutical expenditure. This was accomplished through the execution of regulations to encourage the use of generic drugs in the past decade.

Rising number of M&A, partnerships, and collaborations among leading manufacturers including Teva Pharmaceuticals, Glenmark Specialty S.A., and Hikma Pharmaceuticals PLC is another major factor propelling the growth. For instance, in January 2022, Glenmark Specialty S.A., a Swiss subsidiary of Glenmark Pharmaceuticals Ltd., partnered with Lotus International Pte. Ltd. for marketing Ryaltris nasal spray in Vietnam, Hong Kong, and Singapore. Under this agreement, Glenmark Specialty S.A. will manufacture and supply Ryaltris, and Lotus International Pte. Ltd. will commercialize the product. Similarly, in February 2020, Glenmark Specialty signed a licensing agreement with Hikma Pharmaceuticals PLC to commercialize Ryaltrisin in the U.S.

Extensive research in the respiratory drug discovery and generic product approvals of inhalation and nasal drugs by pharmaceutical companies are projected to fuel growth. For instance, in March 2021, Cipla Inc. received ANDA approval from the U.S. FDA for Sumatriptan Nasal Spray, a generic equivalent of Imitrex Nasal Spray indicated for migraine treatment. In addition, in May 2020, the company received Competitive Generic Therapy designation from FDA along with ANDA approval for Dihydroergotamine Mesylate Nasal Spray, a generic version of Migranal.

Inhalation And Nasal Spray Generic Drugs Market Report Highlights:

• By drug class, the bronchodilators segment led the market with the largest revenue share of 29.84% in 2024. The growth of the bronchodilator drug segment in the global market is expected to be driven by the increasing demand for quick-relief treatments for asthma and other respiratory conditions
• Based on indication, the asthma segment led the market with the largest revenue share of 42.85% in 2024.
• Based on patient demographics, the adult patient segment led the market with the largest revenue share of 43.50% in 2024.
• Based on end-use, the homecare segment led the market with the largest revenue share of 55.86% in 2024.
• Based on distribution channel, the retail pharmacies segment led the market with the largest revenue share of 56.96% in 2024.
• North America inhalation and nasal spray generic drugs market dominated the inhalation and nasal spray generic drugs market with the revenue share of 38.54% in 2024.

Table Of Contents

Chapter 1. Methodology And Scope

• 1.1. Market Segmentation & Scope
• 1.2. Segment Definitions
  • 1.2.1. Drug Class
  • 1.2.2. Indication
  • 1.2.3. Patient Demographics
  • 1.2.4. End Use
  • 1.2.5. Distribution Channel
  • 1.2.6. Regional Scope
  • 1.2.7. Estimates And Forecasts Timeline
• 1.3. Research Methodology
• 1.4. Information Procurement
  • 1.4.1. Purchased Database
  • 1.4.2. Gvr's Internal Database
  • 1.4.3. Secondary Sources
  • 1.4.4. Primary Research
  • 1.4.5. Details Of Primary Research
    • 1.4.5.1. Data For Primary Interviews In North America
    • 1.4.5.2. Data For Primary Interviews In Europe
    • 1.4.5.3. Data For Primary Interviews In Asia Pacific
    • 1.4.5.4. Data For Primary Interviews In Latin America
    • 1.4.5.5. Data For Primary Interviews In Mea
• 1.5. Information Or Data Analysis
  • 1.5.1. Data Analysis Models
• 1.6. Market Formulation & Validation
• 1.7. Model Details
  • 1.7.1. Commodity Flow Analysis (Model 1)
  • 1.7.2. Approach 1: Commodity Flow Approach
  • 1.7.3. Volume Price Analysis (Model 2)
  • 1.7.4. Approach 2: Volume Price Analysis
• 1.8. List Of Secondary Sources
• 1.9. List Of Primary Sources
• 1.10. Objectives

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Outlook
  • 2.2.1. Drug Class And Indication Outlook
  • 2.2.2. Patient Demographics And End Use
  • 2.2.3. Distribution Channel Outlook
• 2.3. Competitive Insights

Chapter 3. Inhalation And Nasal Spray Generic Drugs Market Variables, Trends & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent Market Outlook
  • 3.1.2. Related/Ancillary Market Outlook
• 3.2. Market Dynamics
  • 3.2.1. Market Driver Analysis
    • 3.2.1.1. Rising Incidence Of Respiratory Disease
    • 3.2.1.2. Rising Awareness About Disease
    • 3.2.1.3. Technological Advancement In Drug Development And Delivery
  • 3.2.2. Market Restraint Analysis
    • 3.2.2.1. Low Adoption Of Treatment In Low Middle Income Countries
    • 3.2.2.2. High Competition And Low Profit Margin
• 3.3. Inhalation And Nasal Spray Generic Drugs Market Analysis Tools
  • 3.3.1. Industry Analysis - Porter's
    • 3.3.1.1. Supplier Power
    • 3.3.1.2. Buyer Power
    • 3.3.1.3. Substitution Threat
    • 3.3.1.4. Threat Of New Entrant
    • 3.3.1.5. Competitive Rivalry
  • 3.3.2. Pestel Analysis
    • 3.3.2.1. Political Landscape
    • 3.3.2.2. Technological Landscape
    • 3.3.2.3. Economic Landscape

Chapter 4. Inhalation And Nasal Spray Generic Drugs Market: Drug Class Estimates & Trend Analysis

• 4.1. Segment Dashboard
• 4.2. Global Inhalation And Nasal Spray Generic Drugs Market: Drug Class Movement Analysis
• 4.3. Global Inhalation And Nasal Spray Generic Drugs Market Estimates And Forecasts, By Drug Class, Revenue (USD Million)
• 4.4. Bronchodilators
  • 4.4.1. Bronchodilators Market Estimates And Forecasts 2018 To 2030 (USD Million)
• 4.5. Combination Drugs
  • 4.5.1. Combination Drugs Market Estimates And Forecasts 2018 To 2030 (USD Million)
• 4.6. Corticosteroids
  • 4.6.1. Corticosteroids Market Estimates And Forecasts 2018 To 2030 (USD Million)
• 4.7. Decongestant Sprays
  • 4.7.1. Decongestant Sprays Market Estimates And Forecasts 2018 To 2030 (USD Million)
• 4.8. Antihistamines
  • 4.8.1. Antihistamines Market Estimates And Forecasts 2018 To 2030 (USD Million)
• 4.9. Others
  • 4.9.1. Others Market Estimates And Forecasts 2018 To 2030 (USD Million)

Chapter 5. Inhalation And Nasal Spray Generic Drugs Market: Indication Estimates & Trend Analysis

• 5.1. Segment Dashboard
• 5.2. Global Inhalation And Nasal Spray Generic Drugs Market: Indication Movement Analysis
• 5.3. Global Inhalation And Nasal Spray Generic Drugs Market Estimates And Forecasts, By Indication, Revenue (USD Million)
• 5.4. Asthma
  • 5.4.1. Asthma Market Estimates And Forecasts 2018 To 2030 (USD Million)
• 5.5. Chronic Obstructive Pulmonary Disease (Copd)
  • 5.5.1. Chronic Obstructive Pulmonary Disease (Copd) Market Estimates And Forecasts 2018 To 2030 (USD Million)
• 5.6. Allergic Rhinitis
  • 5.6.1. Allergic Rhinitis Market Estimates And Forecasts 2018 To 2030 (USD Million)
• 5.7. Others
  • 5.7.1. Others Market Estimates And Forecasts 2018 To 2030 (USD Million)

Chapter 6. Inhalation And Nasal Spray Generic Drugs Market: Patient Demographics Estimates & Trend Analysis

• 6.1. Segment Dashboard
• 6.2. Global Inhalation And Nasal Spray Generic Drugs Market: Patient Demographics Movement Analysis
• 6.3. Global Inhalation And Nasal Spray Generic Drugs Market Estimates And Forecasts, By Patient Demographics, Revenue (USD Million)
• 6.4. Adult Patient
  • 6.4.1. Adult Patient Market Estimates And Forecasts 2018 To 2030 (USD Million)
• 6.5. Pediatric Patient
  • 6.5.1. Pediatric Patient Market Estimates And Forecasts 2018 To 2030 (USD Million)
• 6.6. Geriatric Patient
  • 6.6.1. Geriatric Patient Market Estimates And Forecasts 2018 To 2030 (USD Million)

Chapter 7. Inhalation And Nasal Spray Generic Drugs Market: End Use Estimates & Trend Analysis

• 7.1. Segment Dashboard
• 7.2. Global Inhalation And Nasal Spray Generic Drugs Market: End Use Movement Analysis
• 7.3. Global Inhalation And Nasal Spray Generic Drugs Market Estimates And Forecasts, By End Use, Revenue (USD Million)
• 7.4. Homecare
  • 7.4.1. Homecare Market Estimates And Forecasts 2018 To 2030 (USD Million)
• 7.5. Hospitals
  • 7.5.1. Hospitals Market Estimates And Forecasts 2018 To 2030 (USD Million)
• 7.6. Others
  • 7.6.1. Others Market Estimates And Forecasts 2018 To 2030 (USD Million)

Chapter 8. Inhalation And Nasal Spray Generic Drugs Market: Distribution Channel Estimates & Trend Analysis

• 8.1. Segment Dashboard
• 8.2. Global Inhalation And Nasal Spray Generic Drugs Market: Distribution Channel Movement Analysis
• 8.3. Global Inhalation And Nasal Spray Generic Drugs Market Estimates And Forecasts, By Distribution Channel, Revenue (USD Million)
• 8.4. Retail Pharmacies
  • 8.4.1. Retail Pharmacies Market Estimates And Forecasts 2018 To 2030 (USD Million)
• 8.5. Hospitals Pharmacies
  • 8.5.1. Hospitals Pharmacies Market Estimates And Forecasts 2018 To 2030 (USD Million)
• 8.6. Online Pharmacies
  • 8.6.1. Online Pharmacies Market Estimates And Forecasts 2018 To 2030 (USD Million)

Chapter 9. Inhalation And Nasal Spray Generic Drugs Market: Regional Estimates & Trend Analysis By Product, Application, And End Use

• 9.1. Regional Dashboard
• 9.2. Market Size & Forecasts Trend Analysis, 2018 To 2030:
• 9.3. North America
  • 9.3.1. U.S.
    • 9.3.1.1. Key Country Dynamics
    • 9.3.1.2. Regulatory Framework/ Reimbursement Structure
    • 9.3.1.3. Competitive Scenario
    • 9.3.1.4. U.S. Market Estimates And Forecasts 2018 To 2030 (USD Million)
  • 9.3.2. Canada
    • 9.3.2.1. Key Country Dynamics
    • 9.3.2.2. Regulatory Framework/ Reimbursement Structure
    • 9.3.2.3. Competitive Scenario
    • 9.3.2.4. Canada Market Estimates And Forecasts 2018 To 2030 (USD Million)
  • 9.3.3. Mexico
    • 9.3.3.1. Key Country Dynamics
    • 9.3.3.2. Regulatory Framework/ Reimbursement Structure
    • 9.3.3.3. Competitive Scenario
    • 9.3.3.4. Mexico Market Estimates And Forecasts 2018 To 2030 (USD Million)
• 9.4. Europe
  • 9.4.1. Uk
    • 9.4.1.1. Key Country Dynamics
    • 9.4.1.2. Regulatory Framework/ Reimbursement Structure
    • 9.4.1.3. Competitive Scenario
    • 9.4.1.4. Uk Market Estimates And Forecasts 2018 To 2030 (USD Million)
  • 9.4.2. Germany
    • 9.4.2.1. Key Country Dynamics
    • 9.4.2.2. Regulatory Framework/ Reimbursement Structure
    • 9.4.2.3. Competitive Scenario
    • 9.4.2.4. Germany Market Estimates And Forecasts 2018 To 2030 (USD Million)
  • 9.4.3. France
    • 9.4.3.1. Key Country Dynamics
    • 9.4.3.2. Regulatory Framework/ Reimbursement Structure
    • 9.4.3.3. Competitive Scenario
    • 9.4.3.4. France Market Estimates And Forecasts 2018 To 2030 (USD Million)
  • 9.4.4. Italy
    • 9.4.4.1. Key Country Dynamics
    • 9.4.4.2. Regulatory Framework/ Reimbursement Structure
    • 9.4.4.3. Competitive Scenario
    • 9.4.4.4. Italy Market Estimates And Forecasts 2018 To 2030 (USD Million)
  • 9.4.5. Spain
    • 9.4.5.1. Key Country Dynamics
    • 9.4.5.2. Regulatory Framework/ Reimbursement Structure
    • 9.4.5.3. Competitive Scenario
    • 9.4.5.4. Spain Market Estimates And Forecasts 2018 To 2030 (USD Million)
  • 9.4.6. Norway
    • 9.4.6.1. Key Country Dynamics
    • 9.4.6.2. Regulatory Framework/ Reimbursement Structure
    • 9.4.6.3. Competitive Scenario
    • 9.4.6.4. Norway Market Estimates And Forecasts 2018 To 2030 (USD Million)
  • 9.4.7. Sweden
    • 9.4.7.1. Key Country Dynamics
    • 9.4.7.2. Regulatory Framework/ Reimbursement Structure
    • 9.4.7.3. Competitive Scenario
    • 9.4.7.4. Sweden Market Estimates And Forecasts 2018 To 2030 (USD Million)
  • 9.4.8. Denmark
    • 9.4.8.1. Key Country Dynamics
    • 9.4.8.2. Regulatory Framework/ Reimbursement Structure
    • 9.4.8.3. Competitive Scenario
    • 9.4.8.4. Denmark Market Estimates And Forecasts 2018 To 2030 (USD Million)
• 9.5. Asia Pacific
  • 9.5.1. Japan
    • 9.5.1.1. Key Country Dynamics
    • 9.5.1.2. Regulatory Framework/ Reimbursement Structure
    • 9.5.1.3. Competitive Scenario
    • 9.5.1.4. Japan Market Estimates And Forecasts 2018 To 2030 (USD Million)
  • 9.5.2. China
    • 9.5.2.1. Key Country Dynamics
    • 9.5.2.2. Regulatory Framework/ Reimbursement Structure
    • 9.5.2.3. Competitive Scenario
    • 9.5.2.4. China Market Estimates And Forecasts 2018 To 2030 (USD Million)
  • 9.5.3. India
    • 9.5.3.1. Key Country Dynamics
    • 9.5.3.2. Regulatory Framework/ Reimbursement Structure
    • 9.5.3.3. Competitive Scenario
    • 9.5.3.4. India Market Estimates And Forecasts 2018 To 2030 (USD Million)
  • 9.5.4. Australia
    • 9.5.4.1. Key Country Dynamics
    • 9.5.4.2. Regulatory Framework/ Reimbursement Structure
    • 9.5.4.3. Competitive Scenario
    • 9.5.4.4. Australia Market Estimates And Forecasts 2018 To 2030 (USD Million)
  • 9.5.5. South Korea
    • 9.5.5.1. Key Country Dynamics
    • 9.5.5.2. Regulatory Framework/ Reimbursement Structure
    • 9.5.5.3. Competitive Scenario
    • 9.5.5.4. South Korea Market Estimates And Forecasts 2018 To 2030 (USD Million)
  • 9.5.6. Thailand
    • 9.5.6.1. Key Country Dynamics
    • 9.5.6.2. Regulatory Framework/ Reimbursement Structure
    • 9.5.6.3. Competitive Scenario
    • 9.5.6.4. Thailand Market Estimates And Forecasts 2018 To 2030 (USD Million)
• 9.6. Latin America
  • 9.6.1. Brazil
    • 9.6.1.1. Key Country Dynamics
    • 9.6.1.2. Regulatory Framework/ Reimbursement Structure
    • 9.6.1.3. Competitive Scenario
    • 9.6.1.4. Brazil Market Estimates And Forecasts 2018 To 2030 (USD Million)
  • 9.6.2. Argentina
    • 9.6.2.1. Key Country Dynamics
    • 9.6.2.2. Regulatory Framework/ Reimbursement Structure
    • 9.6.2.3. Competitive Scenario
    • 9.6.2.4. Argentina Market Estimates And Forecasts 2018 To 2030 (USD Million)
• 9.7. Mea
  • 9.7.1. South Africa
    • 9.7.1.1. Key Country Dynamics
    • 9.7.1.2. Regulatory Framework/ Reimbursement Structure
    • 9.7.1.3. Competitive Scenario
    • 9.7.1.4. South Africa Market Estimates And Forecasts 2018 To 2030 (USD Million)
  • 9.7.2. Saudi Arabia
    • 9.7.2.1. Key Country Dynamics
    • 9.7.2.2. Regulatory Framework/ Reimbursement Structure
    • 9.7.2.3. Competitive Scenario
    • 9.7.2.4. Saudi Arabia Market Estimates And Forecasts 2018 To 2030 (USD Million)
  • 9.7.3. Uae
    • 9.7.3.1. Key Country Dynamics
    • 9.7.3.2. Regulatory Framework/ Reimbursement Structure
    • 9.7.3.3. Competitive Scenario
    • 9.7.3.4. Uae Market Estimates And Forecasts 2018 To 2030 (USD Million)
  • 9.7.4. Kuwait
    • 9.7.4.1. Key Country Dynamics
    • 9.7.4.2. Regulatory Framework/ Reimbursement Structure
    • 9.7.4.3. Competitive Scenario
    • 9.7.4.4. Kuwait Market Estimates And Forecasts 2018 To 2030 (USD Million)

Chapter 10. Competitive Landscape

• 10.1. Recent Developments & Impact Analysis, By Key Market Participants
• 10.2. Company/Competition Categorization
• 10.3. Vendor Landscape
  • 10.3.1. Key Company Market Share Analysis, 2024
  • 10.3.2. Teva Pharmaceuticals Industries Ltd
    • 10.3.2.1. Company Overview
    • 10.3.2.2. Financial Performance
    • 10.3.2.3. Product Benchmarking
    • 10.3.2.4. Strategic Initiatives
  • 10.3.3. Viatris Inc.
    • 10.3.3.1. Company Overview
    • 10.3.3.2. Financial Performance
    • 10.3.3.3. Product Benchmarking
    • 10.3.3.4. Strategic Initiatives
  • 10.3.4. Akorn Operating Company Llc.
    • 10.3.4.1. Company Overview
    • 10.3.4.2. Financial Performance
    • 10.3.4.3. Product Benchmarking
    • 10.3.4.4. Strategic Initiatives
  • 10.3.5. Cipla
    • 10.3.5.1. Company Overview
    • 10.3.5.2. Financial Performance
    • 10.3.5.3. Product Benchmarking
    • 10.3.5.4. Strategic Initiatives
  • 10.3.6. Sandoz Group Ag
    • 10.3.6.1. Company Overview
    • 10.3.6.2. Financial Performance
    • 10.3.6.3. Product Benchmarking
    • 10.3.6.4. Strategic Initiatives
  • 10.3.7. Apotex Inc.
    • 10.3.7.1. Company Overview
    • 10.3.7.2. Financial Performance
    • 10.3.7.3. Product Benchmarking
    • 10.3.7.4. Strategic Initiatives
  • 10.3.8. Hikma Pharmaceuticals Plc
    • 10.3.8.1. Company Overview
    • 10.3.8.2. Financial Performance
    • 10.3.8.3. Product Benchmarking
    • 10.3.8.4. Strategic Initiatives
  • 10.3.9. Beximco Pharmaceuticals Ltd
    • 10.3.9.1. Company Overview
    • 10.3.9.2. Financial Performance
    • 10.3.9.3. Product Benchmarking
    • 10.3.9.4. Strategic Initiatives
  • 10.3.10. Sun Pharmaceutical Industries Ltd
    • 10.3.10.1. Company Overview
    • 10.3.10.2. Financial Performance
    • 10.3.10.3. Product Benchmarking
    • 10.3.10.4. Strategic Initiatives